Cold Agglutinin Disease Animation
SCIENTIFIC ANIMATION
Cold agglutinin disease, (CAD), is a rare form of autoimmune hemolytic anemia, where the body mistakenly recognizes the antigens on the surface of red blood cells as foreign. This leads to extravascular and intravascular hemolysis, and a range of severe symptoms, including acrocyanosis, extreme fatigue, dyspnea, and hemoglobinuria.
The objective of the animation was to help educate Health Care Professionals on the mechanism of disease for cold agglutinin disease.
The animation was used at The American Society of Hematology and is now featured on the Sanofi Genzyme disease education website, understandingcad.com.
This animation has won 10 industry awards for the quality of animation.
Are you interested in seeing how our award-winning medical animation can help you?
Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.
TESTIMONIALS
‘‘For experts, there’s limited time in which they will interact with this content, so getting a message across quickly is crucial, and this medium does it very well.’’
Product Manager, GSK
‘‘Their turnaround time sets them apart from the rest of the field. The fact they can turnaround lots of comments in a couple of days is impressive, whereas that took weeks with other agencies we worked with. They’re well above the benchmark.’’
Oncology Clinical Liaison, Bristol-Myers Squibb
‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics
‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen
